Could a platelet-boosting drug improve blood counts in certain blood cancers?
Disease control
Terminated
This phase 2 trial tests whether eltrombopag, a drug already approved for other blood disorders, can improve blood cell counts in people with low-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) who have a mutation in the TET2 gene. Participants take…
Phase: PHASE2 • Sponsor: Abhay Singh, MD MPH • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC